Bionor announces additions to the executive management team and interim CFO

(Oslo, 27.03.2015) Bionor Pharma ASA (OSE:BIONOR) announces new members of the executive management team joining CEO, Dr. David Horn Solomon.

The new members of the Company’s executive management are all seasoned executives with prior experience from listed healthcare companies. Joining the team are:

Barbara A. Ruskin, Ph.D., J.D. - Senior Vice President, General Counsel and Chief Patent Officer

Dr. Barbara Ruskin joins Bionor on April 1, 2015. Dr. Ruskin has acted for over two decades advising diverse clients in the biotechnology and pharmaceutical industries.  She has broad expertise in worldwide patent portfolio management, litigation strategies, corporate transactions and due diligence on behalf of companies and investors. She holds a J.D. from Fordham University School of Law (New York, NY), a Ph.D. in Biochemistry and Molecular Biology from Harvard University (Cambridge, MA) and a B.A. in Biochemistry from the University of California, Berkeley (Berkeley, CA).  She is admitted to practice law in New York State and is a registered U.S. patent attorney. In addition to serving as Chief Patent Officer, Barbara will oversee all legal affairs for Bionor.

Kamilla Rolsted, Ph.D., MBA -  Senior Vice President, Chief Strategy and Business Officer

Dr. Kamilla Rolsted joins Bionor on April 1, 2015. Dr. Rolsted has more than 15 years of experience from academia and the pharmaceutical industry, and has held various scientific and managerial positions. Most recently at Zealand Pharma (Nasdaq CO: ZEAL), where Kamilla served as Director, heading Strategy and Planning. Dr. Rolsted is a certified pharmacist, holds a Ph.D. in drug metabolism from the University of Copenhagen and an executive MBA from Copenhagen Business School. Kamilla will be responsible for strategy and business development at Bionor.

Søren Keller - Senior Vice President, Chief Operating Officer and Interim Chief Financial Officer

Søren Keller has extensive experience as head of operations in both public and private research intensive organizations. Prior to joining Bionor, Søren served as director and general counsel to the management at Zealand Pharma A/S (Nasdaq CO: ZEAL).  Søren Keller received his master of Business Administration and Commercial Law from Copenhagen Business School (CBS) and continues to serve as a part-time lecturer at CBS. Søren will be responsible for all operations at Bionor. Additionally, Søren will serve as Interim CFO until the search for a permanent CFO is completed.

David Solomon, President and CEO commented “I am delighted that Barbara Ruskin, Kamilla Rolsted and Søren Keller have joined Bionor. Together, they bring a wealth of experience to advance therapeutic vaccines for Bionor, and specifically will add operational strength to get our HIV functional cure approach advanced to patients and the markets. ”

Lars H. Høie, Chairman of the Board of Directors, says “With a new and proven CEO in place in David Solomon, it is exciting to now have his experienced and able management team also working to drive value for Bionor and bring important solutions to HIV patients. Barbara, Kamilla and Søren are significant additions to Bionor to advance the company’s mission and on behalf of the Board, I welcome them to the company.”

Contact:
Cecilie Grue 
Director of Legal Affairs
E-mail: cg@bionorpharma.com
Phone: +4799162486

David Horn Solomon
CEO
E-mail: dhs@bionorpharma.com
Phone: +45 22 20 63 00

About Bionor
Bionor Pharma ASA is a leading biotechnology company listed on the Oslo Stock Exchange (OSE:BIONOR). The Company’s focus is the research and development of peptide based vaccines against viral diseases, primarily HIV. Bionor’s current clinical development pipeline comprises two vaccine candidates for the treatment of HIV, Vacc-4x and Vacc-c5. Vacc-4x is one of the furthest advanced therapeutic vaccines in the HIV space and has demonstrated a reduction of viral load in a large randomized controlled phase II trial and is currently being investigated in two phase II trials in collaboration with Celgene Inc.